PIPELINE
We will strive to become a global company that contributes to improving the quality of life.
PIPELINE
Holosmedic is developing the world's first customized medicine to drug resistance based on anticancer resistance mechanisms.
- Pre-Clinical Pipeline
- First-in-class HLM2101 is an oral drug used in combination with standard treatment for patients suffering from recurrent ovarian cancer and for whom there is no treatment due to existing drug resistance.
- Discovery Pipeline
- We are developing exclusive medicine for the treatment of triple-negative breast cancer and targeting Tagrisso resistance.
| Compound | Indication | Discovery | Pre-Clinical | Phase I | |
|---|---|---|---|---|---|
Anti-Cancer Drug (Small Molecule) |
HLM2101 |
Ovarian cancer |
|||
Cervical cancer |
|||||
HLM2202 |
TNBC |
||||
HLM2203 |
Lung cancer |